Brookline Capital Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital analyst Tyler Bussian has initiated coverage on Annovis Bio (NYSE:ANVS) with a Buy rating and set a price target of $35.
November 10, 2023 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Annovis Bio receives a Buy rating from Brookline Capital with a price target of $35, indicating a positive outlook from the analyst.
The initiation of coverage by an analyst with a Buy rating typically suggests a positive outlook on the stock's future performance. The price target of $35 implies a significant upside potential from the current trading price, which could attract investor interest and potentially drive up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100